CombiMatrix
Corporation (CBMX) is a biotechnology company that specializes in the
development of diagnostic tests and services for prenatal and
postnatal genetic abnormalities. The company's focus is on the
development of its flagship product, the CombiSNP microarray-based
diagnostic test, which is designed to detect chromosomal abnormalities
in fetuses.
The CombiSNP test is used to screen for chromosomal
abnormalities that can lead to genetic disorders such as Down
syndrome, as well as to identify potential genetic risks for other
conditions. The test is also used to help identify the cause of
recurrent miscarriages.
In addition to the CombiSNP test,
CombiMatrix offers a range of genetic testing services, including
pre-implantation genetic diagnosis (PGD) and array comparative genomic
hybridization (aCGH). The company's PGD services are used to screen
embryos prior to in vitro fertilization (IVF) to identify those with
genetic abnormalities. The aCGH service is used to detect genetic
abnormalities in cancer cells and to help identify the best course of
treatment.
CombiMatrix operates in the United States and
internationally, with laboratories located in Irvine, California and
Hyderabad, India. The company's customer base includes healthcare
providers, IVF clinics, and research institutions.
CombiMatrix
was founded in 1995 and went public in 2006. In 2017, the company was
acquired by Invitae Corporation, a leading provider of genetic testing
services. The acquisition was seen as a strategic move by Invitae to
expand its product offerings and increase its customer base.
Overall, CombiMatrix's focus on developing diagnostic tests for
genetic abnormalities positions the company well to benefit from the
growing demand for personalized medicine and genetic testin
|
